Gene expression during normal and FSHD myogenesis

BMC Medical Genomics

Table 3 Some pathways and functional terms overrepresented among FSHD-dysregulated genes.

Functional terms^a	Mb or Mt	No. of up- or dnreg. genes	Ratio^b
RNA-induced silencing complex	Mt	4 dn	0.80
	Mb	1 dn	0.20
Fatty acid elongation in mitochondria	Mb	7 up	0.44
	Mt	2 up	0.13
Extracellular matrix	Mt	35 up, 1 dn	0.30
	Mb	4 up, 2 dn	0.05
NRF2-mediated oxidative stress response	Mt	15 up, 7 dn	0.13
	Mb	7 up	0.04
HIF1α Signaling	Mt	6 up, 7 dn	0.12
	Mb	5 up	0.05
Regulation of actin-based motility by Rho	Mt	9 up, 3 dn	0.10
	Mb	6 up	0.07
Mitochondrial matrix	Mt	18 up, 5 dn	0.11
	Mb	22 up, 1 dn	0.11
Oxidative phosphorylation	Mt	18 up	0.16
	Mb	11 up	0.09
Induction of apoptosis	Mt	13 up, 5 dn	0.09
	Mb	8 up, 2 dn	0.05
Anti-apoptosis	Mt	16 up, 3 dn	0.10
	Mb	4 up	0.02

^aOverrepresented functional terms for genes up- or downregulated (p < 0.01) in FSHD vs. control myoblasts (Mb) or myotubes (Mt) were identified by bioinformatics programs. Details and the names of the dysregulated genes are given in Additional File 8 Table S5.
^bThe number of genes for a given pathway or GO-term that were up- or downregulated in FSHD vs. control myogenic cells/the total number of genes for that pathway or GO-term that were included in the microarray.